Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Maher Albitar"'
Autor:
Babak Shahbaba, Kirk J. Wojno, Edward Uchio, Neal D. Shore, Wanlong Ma, Donald Moylan, Maher Albitar, Lars Lund, Søren Feddersen
Publikováno v:
Albitar, M, Ma, W, Lund, L, Shahbaba, B, Uchio, E, Feddersen, S, Moylan, D, Wojno, K & Shore, N 2018, ' Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer ', The Prostate, vol. 78, no. 4, pp. 294-299 . https://doi.org/10.1002/pros.23473
BACKGROUND: Distinguishing between low- and high-grade prostate cancers (PCa) is important, but biopsy may underestimate the actual grade of cancer. We have previously shown that urine/plasma-based prostate-specific biomarkers can predict high grade
Autor:
Maher Albitar, Fahad Alsharif, Mahmoud Aljurf, Claudia Ulrike Walter, Abdullah Al-Jefri, Hassan El-Solh, Asim F. Belgaumi, Hazza A Alzahrani, Walid Rasheed, Ghuzayel Aldawsari, Amal Al-Seraihy, Mouhab Ayas, Ali Al-Ahmari, Hala Abalkhail, Said Y Mohamed
Publikováno v:
Biotechnology Research International
Background. We studied DNA chimerism in cell-free DNA (cfDNA) in patients treated with HSCT. Methods. Chimerism analysis was performed on CD3+ cells, polymorphonuclear (PMN) cells, and cfDNA using 16 small tandem repeat loci. The resulting labeled PC
Publikováno v:
Current Drug Targets. 11:994-999
Here we review phospho-specific, quantitative flow cytometry approach as a rapid and reliable tool for measuring intracellular signaling proteins with potential applications in monitoring efficacy of targeted therapy. The single cell, multiparameter
Autor:
Maher Albitar, Ivan De Dios, Baback Shahbaba, Nicholas Stavrou, Vincent Funari, Mohammad Reza Sheikholeslami, Sucha Sudarsanam, Wanlong Ma, Forrest Blocker
Publikováno v:
Journal of Clinical Oncology. 36:3088-3088
3088Background: Predictive biomarkers for selecting of patients who may benefit or experience serious adverse effects from checkpoint blockade therapy are urgently needed. These biomarkers may vary...
Autor:
Maher Albitar, William G. Wierda, Gautam Borthakur, Deborah A. Thomas, Alessandra Ferrajoli, Hagop M. Kantarjian, Jorge E. Cortes, Stefan Faderl, Farhad Ravandi, Francis J. Giles, Sherry Pierce, Srdan Verstovsek, Steven M. Kornblau
Publikováno v:
British Journal of Haematology. 136:624-627
Summary The haematopoietic cell transplantation comorbidity index (HCTCI) predicts nonrelapse mortality and overall survival (OS) post-stem cell transplantation. HCTCI scores were assessed in 177 patients over 60 years of age receiving acute myeloid
Autor:
Cindy Ippoliti, Issa F. Khouri, Maher Albitar, Y. C. Ma, Richard E. Champlin, Rima M. Saliba, Michael J. Keating
Publikováno v:
Bone Marrow Transplantation. 33:833-837
Alemtuzumab is effective in reducing the risk of acute graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (ASCT). Alemtuzumab may also delay immune reconstitution and reduce graft-versus-leukemia effects. The optimal dose has
Autor:
Deborah A. Thomas, Francis J. Giles, Michael J. Keating, Stefan Faderl, Hagop M. Kantarjian, Maher Albitar, Jorge E. Cortes, Susan O'Brien, Elihu H. Estey
Publikováno v:
British Journal of Haematology. 123:436-441
Thalidomide is a putative anti-angiogenesis agent that has significant anti-tumour activity in haematological malignancies with increased bone marrow angiogenesis, including multiple myeloma (MM) and myelodysplastic syndromes (MDS). Increased levels
Autor:
Lewis Silverman, Guillermo Garcia-Manero, Paul J. Shami, Judith E. Karp, Maurizio Zangari, Maher Albitar, Khuda D. Khan, Deborah A. Thomas, Hagop Kantarjian, Jeffrey E. Lancet, Alison T. Stopeck, Julie M. Cherrington, Maureen A. Cooper, Alison L. Hannah, Francis J. Giles
Publikováno v:
Cancer. 97:1920-1928
BACKGROUND Increased bone marrow angiogenesis and vascular endothelial growth factor (VEGF) levels are of adverse prognostic significance in patients with myeloproliferative disorders (MPD), including agnogenic myeloid metaplasia (AMM), chronic myelo
Autor:
Stefan Faderl, Guillermo Garcia-Manero, Jorge Cortes, Alessandra Ferrajoli, Srdan Verstovsek, Susan O'Brien, Hagop Kantarjian, Apostolia M. Tsimberidou, Michael J. Keating, Deborah A. Thomas, William Wierda, Maher Albitar, Yesid Alvarado, Francis J. Giles
Publikováno v:
Cancer. 97:1711-1720
BACKGROUND Therapy for patients with Richter syndrome (RS) or fludarabine-refractory chronic lymphocytic leukemia (CLL) is unsatisfactory. A Phase II study was conducted to evaluate an alternating combination cytotoxic regimen given with rituximab an
Autor:
Michael J. Keating, Elihu H. Estey, Stefan Faderl, Srdan Verstovsek, Francis J. Giles, Hagop M. Kantarjian, Guillermo Garcia-Manero, Jorge E. Cortes, Susan O'Brien, Maher Albitar, Deborah A. Thomas, Apostolia Maria Tsimberidou
Publikováno v:
Cancer. 97:1481-1487
BACKGROUND Gemtuzumab is used to treat patients with previously untreated or recurrent acute myelogenous leukemia (AML). The fludarabine and cytarabine (ara-C) regimen is active in these patients. Resistance to gemtuzumab is associated with blast mul